Zamicastat
Tier C — Watch / tradeZamicastat
Targets：DBH
Indications (approved)：Pulmonary arterial hypertension, Lung disease, Heart failure
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ZAMIC-001 | 760173-05-5 | (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione |
| ZAMIC-002 | 100-52-7Available | benzaldehyde |
Frequently asked questions
What are the approved indications of Zamicastat?
Approved indications include: Pulmonary arterial hypertension, Lung disease, Heart failure.
When does the Zamicastat patent expire?
No public expiry year is available for Zamicastat yet; this page updates once verified.
How many synthesis routes are recorded for Zamicastat?
1 synthesis routes are recorded; the shortest is 1 steps with 1.25 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Zamicastat intermediates?
1 intermediate CAS of Zamicastat are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Zamicastat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08